AVTX
Avalo Therapeutics Inc
3월 13일 4:00 PM ET (한국 3/14 05:00)
$15.80
-0.91 ▼ -5.45%
🌙 3월 13일 6:50 PM ET (한국 3/14 07:50)
$14.90
-0.90 ▼ -5.70%
| Index | - | P/E | - | EPS (ttm) | -8.73 | Insider Own | 14.2% | Shs Outstand | 0.02B | Perf Week | -8.72% |
| Market Cap | 0.29B | Forward P/E | - | EPS next Y | 16.85% | Insider Trans | -0.43% | Shs Float | 0.02B | Perf Month | 10.1% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | -1.46 | Inst Own | 98.27% | Short Float | 23.19% | Perf Quarter | -20.8% |
| Income | -0.10B | P/S | 1539.47 | EPS this Y | 67.9% | Inst Trans | 35.84% | Short Ratio | 8.36 | Perf Half Y | 45.22% |
| Sales | 0.00B | P/B | 3.08 | EPS next 5Y | 41.75% | ROA | -89.35% | Short Interest | 3.68M | Perf YTD | -13% |
| Book/sh | 5.14 | P/C | 2.62 | EPS past 3/5Y | 79.39% 56.49% | ROE | -174.79% | 52W High | -23.74% ($20.72) | Perf Year | 112.94% |
| Cash/sh | 6.03 | P/FCF | - | Sales past 3/5Y | -56.61% -42.05% | ROIC | -106.63% | 52W Low | 366.08% ($3.39) | Perf 3Y | -97.25% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 94.03% | Gross Margin | -116.15% | Volatility(W/M) | 6.99% 8.86% | Perf 5Y | -99.84% |
| Dividend TTM | - | EV/Sales | 965 | Sales Y/Y TTM | -76.59% | Oper. Margin | -34632.29% | ATR (14) | 1.32 | Perf 10Y | -99.84% |
| Dividend Ex-Date | - | Quick Ratio | 14.28 | EPS Q/Q | 22.82% | Profit Margin | -52019.79% | RSI (14) | 45.11 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.28 | Sales Q/Q | -100% | SMA20 | -4.66% ($16.57) | Beta | 0.9 | Target Price | $36.11 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 11000000 | SMA50 | -1.32% ($16.01) | Rel Volume | 0.71 | Prev Close | $16.71 |
| Employees | 23 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -32.05% - | SMA200 | 25.54% ($12.59) | Avg Volume(3M) | 0.44M | Price | $15.8 |
| IPO | 2015/11/13 | Option/Short | Yes/Yes | Trades | 3670 | Volume | 314,461 | Change | -5.45% |
뉴스 로딩 중...